Analysts See $0.53 EPS for TransUnion (TRU); MEDOVEX (MDVX) Shorts Increased By 70.34%

TransUnion (NYSE:TRU) Logo

Analysts expect TransUnion (NYSE:TRU) to report $0.53 EPS on April, 19.They anticipate $0.00 EPS change or 0.00% from last quarter’s $0.53 EPS. TRU’s profit would be $98.42M giving it 30.72 P/E if the $0.53 EPS is correct. After having $0.63 EPS previously, TransUnion’s analysts see -15.87% EPS growth. The stock increased 0.11% or $0.07 during the last trading session, reaching $65.13. About 1.45M shares traded. TransUnion (NYSE:TRU) has risen 12.51% since March 17, 2018 and is uptrending. It has outperformed by 8.14% the S&P500. Some Historical TRU News: 20/04/2018 – TRANSUNION-QTRLY TOTAL REVENUE WAS $537 MILLION, INCREASE OF 18 PERCENT (17 PERCENT ON A CONSTANT CURRENCY BASIS) COMPARED WITH FIRST QUARTER OF 2017; 06/03/2018 – TRANSUNION – OFFERING EXPECTED TO CLOSE ON MARCH 8; 20/04/2018 – GTCR SALE OF CALLCREDIT TO TRANSUNION; 20/04/2018 – S&PGRBulletin: TransUnion Rtgs Unafctd By Acqstn Of Callcredit; 20/04/2018 – TRANSUNION – DEAL FOR £1 BLN; 20/04/2018 – TRANSUNION: STRONG 1Q 2018 RESULTS, PACT TO BUY CALLCREDIT; 16/05/2018 – Percentage of Consumers Shopping for Personal Auto Insurance Reaches Four-Year Low; 29/05/2018 – Data Shows Mortgage Originations Volumes Decreased from Previous Quarter with Slight Decline in Risk-Taking Consumption Overall; 20/04/2018 – TRANSUNION – FOR THE SECOND QUARTER OF 2018, REVENUE IS EXPECTED TO BE BETWEEN $534 MILLION AND $539 MILLION; 20/04/2018 – TransUnion Sees 2Q Adjusted EBITDA $208M-$211M

MEDOVEX CORP (OTCMKTS:MDVX) had an increase of 70.34% in short interest. MDVX’s SI was 20,100 shares in March as released by FINRA. Its up 70.34% from 11,800 shares previously. With 80,900 avg volume, 0 days are for MEDOVEX CORP (OTCMKTS:MDVX)’s short sellers to cover MDVX’s short positions. The stock increased 1.85% or $0.01 during the last trading session, reaching $0.55. About 106,315 shares traded or 36.32% up from the average. MedoveX Corp. (OTCMKTS:MDVX) has 0.00% since March 17, 2018 and is . It has underperformed by 4.37% the S&P500.

Among 5 analysts covering TransUnion (NYSE:TRU), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. TransUnion had 5 analyst reports since October 15, 2018 according to SRatingsIntel. JP Morgan maintained it with “Overweight” rating and $84 target in Wednesday, October 24 report. Atlantic Securities upgraded the stock to “Overweight” rating in Wednesday, October 24 report. As per Monday, January 14, the company rating was maintained by Deutsche Bank. On Monday, October 15 the stock rating was maintained by Morgan Stanley with “Equal-Weight”.

More notable recent TransUnion (NYSE:TRU) news were published by: which released: “TransUnion Investor Day Scheduled for March 12, 2019 NYSE:TRU – GlobeNewswire” on March 05, 2019, also with their article: “TransUnion Declares Fourth-Quarter 2018 Dividend of $0.075 per Share – GlobeNewswire” published on February 21, 2019, published: “FinTechs Continue to Drive Personal Loan Growth – GlobeNewswire” on February 21, 2019. More interesting news about TransUnion (NYSE:TRU) were released by: and their article: “Lenders Around the World Seek Help From Data Scientists to Improve Speed and Efficacy of Analytics – GlobeNewswire” published on March 05, 2019 as well as‘s news article titled: “Canadian Consumer Credit Market Finishes 2018 Strong, Though Some Areas of Softness Emerge – GlobeNewswire” with publication date: February 20, 2019.

TransUnion provides risk and information solutions. The company has market cap of $12.10 billion. The firm operates in three divisions: U.S. It has a 44.86 P/E ratio. Information Services , International, and Consumer Interactive.

More notable recent MedoveX Corp. (OTCMKTS:MDVX) news were published by: which released: “Medovex changes name to Blue Zone Health – Seeking Alpha” on February 04, 2019, also with their article: “Medovex names William E. Horne CEO and Chairman of the Board – Seeking Alpha” published on October 09, 2018, published: “Medovex to acquire business segments of Regenerative Medicine Solutions – Seeking Alpha” on October 16, 2018. More interesting news about MedoveX Corp. (OTCMKTS:MDVX) were released by: and their article: “Major Downside For Medovex Amid Stock Promotion And Questionable M&A – Seeking Alpha” published on August 07, 2017 as well as‘s news article titled: “Medovex: Riding A Major Investor To Success – Seeking Alpha” with publication date: May 05, 2015.

TransUnion (NYSE:TRU) Ratings Chart